Registration for this webinar has closed. Watch the recording here!
Azedra was approved by the Food and Drug Administration (FDA) five years ago. What have we learned through research since that time? Who is a good candidate for this treatment? How is it administered, and what are the side effects? OSU’s Dr. Vineeth Sukrithan joins us on Tuesday, July 18th at 12 PM PT/3 PM ET for an in-depth look at the first drug developed specifically for the treatment of pheochromocytoma and paraganglioma, and how it’s used in a clinical setting.